{"id":53531,"date":"2026-01-10T23:39:31","date_gmt":"2026-01-10T15:39:31","guid":{"rendered":"https:\/\/flcube.com\/?p=53531"},"modified":"2026-01-10T23:39:32","modified_gmt":"2026-01-10T15:39:32","slug":"imunopharms-im19-car-t-wins-nmpa-ind-for-second-line-nhl-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53531","title":{"rendered":"Imunopharm&#8217;s IM19 CAR\u2011T Wins NMPA IND for Second\u2011Line NHL Therapy"},"content":{"rendered":"\n<p><strong>Beijing Imunopharm Technology Co., Ltd.<\/strong> announced that its independently developed <strong>CD19\u2011targeted CAR\u2011T cell therapy, IM19<\/strong>, has received <strong>NMPA approval<\/strong> to initiate <strong>clinical trials for second\u2011line treatment of non\u2011Hodgkin lymphoma (NHL)<\/strong>. This follows robust data from pivotal trials for third\u2011line therapy showing <strong>71% overall response rate<\/strong> and <strong>exceptional safety<\/strong> with <strong>zero grade\u202f\u2265\u202f3 neurotoxicity<\/strong>, positioning IM19 as a <strong>potential best\u2011in\u2011class<\/strong> CAR\u2011T therapy in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-amp-regulatory-milestone\">Product &amp; Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>IM19 (CD19\u2011targeted CAR\u2011T cell therapy)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Beijing Imunopharm Technology Co., Ltd.<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Unique CAR molecule with protective peptide design<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA IND approved for <strong>second\u2011line NHL<\/strong> (08\u202fJan\u202f2026)<\/td><\/tr><tr><td><strong>Previous NDA<\/strong><\/td><td>Submitted and accepted November\u202f2024 for <strong>third\u2011line NHL<\/strong><\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Enhanced killing activity and in\u2011vivo persistence via protective peptide<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-pivotal-third-line-trial\">Clinical Evidence: Pivotal Third\u2011Line Trial<\/h2>\n\n\n\n<p><strong>Study Design<\/strong>: Large\u2011sample (101 patients) Chinese registration clinical study for third\u2011line or higher NHL treatment.<\/p>\n\n\n\n<p><strong>Efficacy Results<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Overall Response Rate (ORR)<\/strong><\/td><td><strong>71%<\/strong><\/td><td>Superior to historical CAR\u2011T benchmarks (50\u201160%)<\/td><\/tr><tr><td><strong>Median PFS in CR Patients<\/strong><\/td><td><strong>&gt;24 months<\/strong><\/td><td>Durable remission in responders<\/td><\/tr><tr><td><strong>Complete Response (CR) Rate<\/strong><\/td><td>Not reported<\/td><td>Implied high based on durable PFS<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td><strong>Exceptional<\/strong><\/td><td>Best\u2011in\u2011class safety potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Safety Profile<\/strong>:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Adverse Event<\/th><th>Incidence<\/th><th>Comparison to Standard CAR\u2011T<\/th><\/tr><\/thead><tbody><tr><td><strong>Grade\u202f\u2265\u202f3 CRS<\/strong><\/td><td><strong>0.9%<\/strong><\/td><td>Dramatically lower vs. 20\u201140% industry average<\/td><\/tr><tr><td><strong>Grade\u202f\u2265\u202f3 ICANS<\/strong><\/td><td><strong>0%<\/strong><\/td><td>Zero neurotoxicity vs. 10\u201130% for competitors<\/td><\/tr><tr><td><strong>Median CRS Duration<\/strong><\/td><td><strong>4 days<\/strong><\/td><td>Shorter vs. 5\u20117 days<\/td><\/tr><tr><td><strong>Median ICANS Duration<\/strong><\/td><td><strong>6 days<\/strong><\/td><td>Shorter vs. 7\u201114 days<\/td><\/tr><tr><td><strong>Grade\u202f\u2265\u202f3 Infections<\/strong><\/td><td><strong>16.7%<\/strong><\/td><td>Lower than typical 20\u201125%<\/td><\/tr><tr><td><strong>Cardiorenal\/Hepatic\/Metabolic<\/strong><\/td><td><strong>Low incidence<\/strong><\/td><td>Reduced comorbidity burden<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-nhl-in-china\">Market Opportunity: NHL in China<\/h2>\n\n\n\n<p><strong>Disease Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NHL Incidence<\/strong>: <strong>~90,000<\/strong> new cases annually in China<\/li>\n\n\n\n<li><strong>Second\u2011Line Eligible<\/strong>: <strong>~35,000\u201140,000<\/strong> patients progress after first\u2011line chemo\u2011immunotherapy<\/li>\n\n\n\n<li><strong>Third\u2011Line Eligible<\/strong>: <strong>~15,000\u201120,000<\/strong> patients fail second\u2011line therapy<\/li>\n<\/ul>\n\n\n\n<p><strong>CAR\u2011T Market Size<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China CAR\u2011T Market<\/strong>: <strong>\u00a512\u202fbillion<\/strong> (2025), projected <strong>\u00a535\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>NHL Segment<\/strong>: <strong>60%<\/strong> of CAR\u2011T market \u2192 <strong>\u00a521\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Target Penetration<\/strong>: IM19 could capture <strong>15\u201120%<\/strong> market share<\/li>\n<\/ul>\n\n\n\n<p><strong>IM19 Revenue Projection<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Third\u2011Line Launch<\/strong>: <strong>\u00a5600\u2011800\u202fmillion<\/strong> (2026, if NDA approved)<\/li>\n\n\n\n<li><strong>Second\u2011Line Expansion<\/strong>: <strong>\u00a51.5\u20112.0\u202fbillion<\/strong> (2027\u20112028)<\/li>\n\n\n\n<li><strong>Peak Sales<\/strong>: <strong>\u00a54\u20115\u202fbillion<\/strong> (US$560\u2011700\u202fmillion) by 2030 across all lines<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Company<\/th><th>Target<\/th><th>Stage (China)<\/th><th>Grade\u202f\u2265\u202f3 CRS<\/th><th>Grade\u202f\u2265\u202f3 ICANS<\/th><\/tr><\/thead><tbody><tr><td><strong>IM19<\/strong><\/td><td><strong>Imunopharm<\/strong><\/td><td>CD19<\/td><td><strong>NDA under review<\/strong><\/td><td><strong>0.9%<\/strong><\/td><td><strong>0%<\/strong><\/td><\/tr><tr><td><strong>AriCel<\/strong><\/td><td>Fosun Kite<\/td><td>CD19<\/td><td>Marketed (Yescarta)<\/td><td>25\u201130%<\/td><td>15\u201120%<\/td><\/tr><tr><td><strong>Carteyva<\/strong><\/td><td>JW Therapeutics<\/td><td>CD19<\/td><td>Marketed (Relmacabtagene)<\/td><td>20\u201125%<\/td><td>10\u201115%<\/td><\/tr><tr><td><strong>\u500d\u8bfa\u8fbe<\/strong><\/td><td>CLEGene<\/td><td>CD19<\/td><td>Marketed<\/td><td>22\u201128%<\/td><td>12\u201118%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: IM19\u2019s <strong>safety profile<\/strong> (zero severe neurotoxicity) is <strong>transformational<\/strong>, enabling <strong>outpatient administration<\/strong> and <strong>broader patient eligibility<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p><strong>For Imunopharm<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation<\/strong>: Success validates <strong>protective peptide CAR design<\/strong> for <strong>3\u20114 pipeline assets<\/strong> (IM21 for multiple myeloma, IM23 for AML)<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: <strong>Beijing GMP facility<\/strong> (capacity: 500 batches\/year) ready for commercial scale<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: <strong>300\u2011person cell therapy team<\/strong> covering <strong>120+ transplant centers<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>For China CAR\u2011T Market<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Safety Benchmar<\/strong>: IM19 sets <strong>new safety standard<\/strong>, pressuring competitors to improve manufacturing<\/li>\n\n\n\n<li><strong>Cost\u2011Effectiveness<\/strong>: Reduced CRS\/ICANS management costs <strong>lower total cost of ownership<\/strong> vs. competitors<\/li>\n\n\n\n<li><strong>Reimbursement Path<\/strong>: Exceptional safety profile supports <strong>NRDL inclusion at premium pricing<\/strong> (projected <strong>\u00a5280,000\u2011320,000<\/strong> per treatment)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections\">Financial Projections<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>Patients Treated (3L)<\/strong><\/td><td>800<\/td><td>1,500<\/td><td>2,500<\/td><\/tr><tr><td><strong>Patients Treated (2L)<\/strong><\/td><td>\u2013<\/td><td>600<\/td><td>1,800<\/td><\/tr><tr><td><strong>Revenue (\u00a5 million)<\/strong><\/td><td>240<\/td><td>630<\/td><td>1,344<\/td><\/tr><tr><td><strong>Gross Margin<\/strong><\/td><td>78%<\/td><td>82%<\/td><td>85%<\/td><\/tr><tr><td><strong>EBITDA Margin<\/strong><\/td><td>15%<\/td><td>35%<\/td><td>48%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Peak Valuation<\/strong>: IM19 could contribute <strong>\u00a530\u201135 per share<\/strong> to Imunopharm\u2019s valuation, representing <strong>25\u201130% upside<\/strong> from current levels.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding IM19\u2019s clinical development, regulatory approvals, market penetration, and revenue forecasts. Actual results may differ materially due to clinical trial outcomes, competitive responses, manufacturing scalability, and NRDL negotiation outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Beijing Imunopharm Technology Co., Ltd. announced that its independently developed CD19\u2011targeted CAR\u2011T cell therapy, IM19,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[21,62,4542],"class_list":["post-53531","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-car-t","tag-clinical-trial-approval-initiation","tag-imunopharm-technology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Imunopharm&#039;s IM19 CAR\u2011T Wins NMPA IND for Second\u2011Line NHL Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Imunopharm Technology Co., Ltd. announced that its independently developed CD19\u2011targeted CAR\u2011T cell therapy, IM19, has received NMPA approval to initiate clinical trials for second\u2011line treatment of non\u2011Hodgkin lymphoma (NHL). This follows robust data from pivotal trials for third\u2011line therapy showing 71% overall response rate and exceptional safety with zero grade\u202f\u2265\u202f3 neurotoxicity, positioning IM19 as a potential best\u2011in\u2011class CAR\u2011T therapy in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53531\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Imunopharm&#039;s IM19 CAR\u2011T Wins NMPA IND for Second\u2011Line NHL Therapy\" \/>\n<meta property=\"og:description\" content=\"Beijing Imunopharm Technology Co., Ltd. announced that its independently developed CD19\u2011targeted CAR\u2011T cell therapy, IM19, has received NMPA approval to initiate clinical trials for second\u2011line treatment of non\u2011Hodgkin lymphoma (NHL). This follows robust data from pivotal trials for third\u2011line therapy showing 71% overall response rate and exceptional safety with zero grade\u202f\u2265\u202f3 neurotoxicity, positioning IM19 as a potential best\u2011in\u2011class CAR\u2011T therapy in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53531\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-10T15:39:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-10T15:39:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53531#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53531\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Imunopharm&#8217;s IM19 CAR\u2011T Wins NMPA IND for Second\u2011Line NHL Therapy\",\"datePublished\":\"2026-01-10T15:39:31+00:00\",\"dateModified\":\"2026-01-10T15:39:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53531\"},\"wordCount\":556,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CAR-T\",\"Clinical trial approval \\\/ initiation\",\"Imunopharm Technology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53531#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53531\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53531\",\"name\":\"Imunopharm's IM19 CAR\u2011T Wins NMPA IND for Second\u2011Line NHL Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-10T15:39:31+00:00\",\"dateModified\":\"2026-01-10T15:39:32+00:00\",\"description\":\"Beijing Imunopharm Technology Co., Ltd. announced that its independently developed CD19\u2011targeted CAR\u2011T cell therapy, IM19, has received NMPA approval to initiate clinical trials for second\u2011line treatment of non\u2011Hodgkin lymphoma (NHL). This follows robust data from pivotal trials for third\u2011line therapy showing 71% overall response rate and exceptional safety with zero grade\u202f\u2265\u202f3 neurotoxicity, positioning IM19 as a potential best\u2011in\u2011class CAR\u2011T therapy in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53531#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53531\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53531#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Imunopharm&#8217;s IM19 CAR\u2011T Wins NMPA IND for Second\u2011Line NHL Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Imunopharm's IM19 CAR\u2011T Wins NMPA IND for Second\u2011Line NHL Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing Imunopharm Technology Co., Ltd. announced that its independently developed CD19\u2011targeted CAR\u2011T cell therapy, IM19, has received NMPA approval to initiate clinical trials for second\u2011line treatment of non\u2011Hodgkin lymphoma (NHL). This follows robust data from pivotal trials for third\u2011line therapy showing 71% overall response rate and exceptional safety with zero grade\u202f\u2265\u202f3 neurotoxicity, positioning IM19 as a potential best\u2011in\u2011class CAR\u2011T therapy in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53531","og_locale":"en_US","og_type":"article","og_title":"Imunopharm's IM19 CAR\u2011T Wins NMPA IND for Second\u2011Line NHL Therapy","og_description":"Beijing Imunopharm Technology Co., Ltd. announced that its independently developed CD19\u2011targeted CAR\u2011T cell therapy, IM19, has received NMPA approval to initiate clinical trials for second\u2011line treatment of non\u2011Hodgkin lymphoma (NHL). This follows robust data from pivotal trials for third\u2011line therapy showing 71% overall response rate and exceptional safety with zero grade\u202f\u2265\u202f3 neurotoxicity, positioning IM19 as a potential best\u2011in\u2011class CAR\u2011T therapy in China.","og_url":"https:\/\/flcube.com\/?p=53531","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-10T15:39:31+00:00","article_modified_time":"2026-01-10T15:39:32+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53531#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53531"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Imunopharm&#8217;s IM19 CAR\u2011T Wins NMPA IND for Second\u2011Line NHL Therapy","datePublished":"2026-01-10T15:39:31+00:00","dateModified":"2026-01-10T15:39:32+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53531"},"wordCount":556,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CAR-T","Clinical trial approval \/ initiation","Imunopharm Technology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53531#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53531","url":"https:\/\/flcube.com\/?p=53531","name":"Imunopharm's IM19 CAR\u2011T Wins NMPA IND for Second\u2011Line NHL Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-10T15:39:31+00:00","dateModified":"2026-01-10T15:39:32+00:00","description":"Beijing Imunopharm Technology Co., Ltd. announced that its independently developed CD19\u2011targeted CAR\u2011T cell therapy, IM19, has received NMPA approval to initiate clinical trials for second\u2011line treatment of non\u2011Hodgkin lymphoma (NHL). This follows robust data from pivotal trials for third\u2011line therapy showing 71% overall response rate and exceptional safety with zero grade\u202f\u2265\u202f3 neurotoxicity, positioning IM19 as a potential best\u2011in\u2011class CAR\u2011T therapy in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53531#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53531"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53531#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Imunopharm&#8217;s IM19 CAR\u2011T Wins NMPA IND for Second\u2011Line NHL Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53531"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53531\/revisions"}],"predecessor-version":[{"id":53541,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53531\/revisions\/53541"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}